{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T22:54:58Z","timestamp":1747176898145,"version":"3.40.5"},"reference-count":44,"publisher":"Informa UK Limited","issue":"9","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Current Medical Research and Opinion"],"published-print":{"date-parts":[[2021,9,2]]},"DOI":"10.1080\/03007995.2021.1933928","type":"journal-article","created":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T09:00:59Z","timestamp":1621933259000},"page":"1667-1675","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Utilization, adherence, and outcomes of 17-alpha hydroxyprogesterone caproate for recurrent spontaneous preterm birth prevention"],"prefix":"10.1080","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3471-6061","authenticated-orcid":false,"given":"Shiyu","family":"Zhang","sequence":"first","affiliation":[{"name":"Health Outcomes Division, College of Pharmacy, The University of Texas at Austin, Austin, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen L.","family":"Rascati","sequence":"additional","affiliation":[{"name":"Health Outcomes Division, College of Pharmacy, The University of Texas at Austin, Austin, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,6,7]]},"reference":[{"key":"e_1_3_4_2_1","unstructured":"WHO. Preterm birth: Key facts; 2018 [cited 2020 Nov 20]. Available from: http:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/preterm-birth."},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60074-4"},{"key":"e_1_3_4_4_1","unstructured":"March of Dimes. Nowhere to go: maternity care deserts across the U.S.2020 report; 2021 [cited 2021 Feb 12] Available from: https:\/\/www.marchofdimes.org\/materials\/MOD2020_REPORT_CARD_and_POLICY_ACTIONS_BOOKLET_FIN.pdf."},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/00016340802005126"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035140"},{"key":"e_1_3_4_7_1","unstructured":"US Food and Drug Administration. FDA briefing document NDA 021945 Hydroxyprogesterone Injection (trade name Makena); 2019 [cited 2020 Nov 20]. Available from: https:\/\/www.fda.gov\/media\/132003\/download."},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e3182723b1b"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2017.01.022"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2020.04.001"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2031055"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2020.1783220"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2031727"},{"key":"e_1_3_4_14_1","unstructured":"AMAG Pharmaceuticals. Comment from AMAG Pharmaceuticals Inc.; 2020 [cited 2021 Feb 12]. Available from: https:\/\/www.regulations.gov\/comment\/FDA-2020-N-2029-0051."},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2020"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2017.02.025"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2015.10.148"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000150560.24297.4f"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41372-019-0401-2"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajogmf.2020.100166"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-3400227"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2007.01.002"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2005.08.014"},{"key":"e_1_3_4_24_1","doi-asserted-by":"crossref","unstructured":"Ngai I Sheen J-J Garretto D et\u00a0al. Progesterone (17\u03b1-hydroxyprogesterone caproate) for prevention of preterm birth and preeclampsia. 2014;123:162S.","DOI":"10.1097\/01.AOG.0000447164.22404.d0"},{"key":"e_1_3_4_25_1","unstructured":"Association of State and Territorial Health Officials. Increasing state health agency capacity to improve 17P utilization; 2015 [cited 2020 Dec 3]. Available from: http:\/\/www.astho.org\/Maternal-and-Child-Health\/ASTHO-17P-Issue-Brief\/."},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2015.12.054"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2015.05.005"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2016.01.180"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2015.01.007"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10995-018-2556-4"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2007.06.032"},{"issue":"7","key":"e_1_3_4_32_1","first-page":"489","article-title":"Pregnancy outcomes of managed Medicaid members prescribed home administration of 17 alpha-hydroxyprogesterone caproate","volume":"29","author":"Lucas B","year":"2012","unstructured":"Lucas B, Poole-Yaeger A, Istwan N, et\u00a0al. Pregnancy outcomes of managed Medicaid members prescribed home administration of 17 alpha-hydroxyprogesterone caproate. Am J Perinatol. 2012;29(7):489\u2013496.","journal-title":"Am J Perinatol"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-1678532"},{"key":"e_1_3_4_34_1","unstructured":"US Food and Drug Administration. CDER proposes withdrawal of approval for Makena; 2020 [cited 2020 Dec 15]. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/cder-proposes-withdrawal-approval-makena."},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00217-8"},{"key":"e_1_3_4_36_1","unstructured":"US Food and Drug Administration. CDER perspective on recently published results of EPPPIC meta-analysis; 2021 [cited 2021 May 1]. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/cder-perspective-recently-published-results-epppic-meta-analysis."},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1676113"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000001738"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2006.06.034"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1080\/14767058.2016.1269164"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2017.05.022"},{"key":"e_1_3_4_42_1","doi-asserted-by":"crossref","first-page":"242","DOI":"10.4103\/2277-9175.168609","article-title":"Evaluation the effect of 17-alpha hydroxyprogesterone caproate on gestational diabetes mellitus in pregnant women at risk for preterm birth","volume":"4","author":"Rouholamin S","year":"2015","unstructured":"Rouholamin S, Zarean E, Sadeghi L. Evaluation the effect of 17-alpha hydroxyprogesterone caproate on gestational diabetes mellitus in pregnant women at risk for preterm birth. Adv Biomed Res. 2015;4:242.","journal-title":"Adv Biomed Res"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2009.06.036"},{"key":"e_1_3_4_44_1","unstructured":"Makena Care Connection AP. Makena (hydroxyprogesterone caproate injection) billing guide; 2018 [cited 2020 Dec 2]. Available from: https:\/\/makenahcp.com\/wp-content\/uploads\/2018\/11\/PP-MKN-US-00408-makena-billing-guide.pdf."},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.114.04484"}],"container-title":["Current Medical Research and Opinion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/03007995.2021.1933928","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T03:55:43Z","timestamp":1699070143000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/03007995.2021.1933928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,7]]},"references-count":44,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9,2]]}},"alternative-id":["10.1080\/03007995.2021.1933928"],"URL":"https:\/\/doi.org\/10.1080\/03007995.2021.1933928","relation":{},"ISSN":["0300-7995","1473-4877"],"issn-type":[{"type":"print","value":"0300-7995"},{"type":"electronic","value":"1473-4877"}],"subject":[],"published":{"date-parts":[[2021,6,7]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-03-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}